MétaCan
Menu
Back to cohort
Record W4403954504 · doi:10.1093/ofid/ofae638

4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results From a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young Adults

2024· article· en· W4403954504 on OpenAlexaff
Terry Nolan, Chiranjiwi Bhusal, Jiřı́ Beran, Mark Bloch, Benhur Şirvan Çetin, Ener Çağrı Dinleyici, Daniel Dražan, Satu Kokko, Susanna Koski, Outi Laajalahti, Joanne M. Langley, Mika Rämet, Peter Richmond, Peter Silas, Bruce Tapiéro, Florence Tiong, Mary Tipton, Benita Ukkonen, Betül Ulukol, Maria Lattanzi, Mariano Di Trapani, Arnold Willemsen, Daniela Toneatto, Ronald Ackerman, Renata Adamovska, Eugene Athan, Kwabena Ayesu, David Bernard, William Byars, Robert Carter, Maia Chakerian, Marije Dalebout, Ferdinandus de Looze, Marc Dionne, Peter Dzongowski, Rand Farjo, Daniel K. Finn, George Freeman, Ryan Gottfredson, Paul Grubb, Anil K. Gupta, Tolga İ̇nce, Robert Jeanfreau, Jake D. Jones, James D. Kellner, Kaia Kiiroja, Isabelle Lechevin, Hemalini Mehta, Sandra Meisalu, Danielle Morelle, Alexander Osowa, Pauliina Paavola, Minesh Patel, Miroslav Pavlasek, Enrique Pelayo, Stéfanie Raulier, Peter Richmond, Walter Rok, Rambod Rouhbakhsh, Manish Sadarangani, Martin Schear, John D. Scott, Ilkka Seppä, William Simon, Martina Spaziererova, Jonathan Staben, Joseph Surber, Marie-Louise Vachon, Noah Vale, Dominique Wauters, Josef Zemanek

Bibliographic record

VenueOpen Forum Infectious Diseases · 2024
Typearticle
Languageen
FieldImmunology and Microbiology
TopicBacterial Infections and Vaccines
Canadian institutionsUniversité de MontréalCentre Hospitalier Universitaire Sainte-JustineNova Scotia Health AuthorityDalhousie University
Fundersnot available
KeywordsMedicineImmunogenicityRandomized controlled trialImmune systemAntibody responseImmunologyInternal medicine

Abstract

fetched live from OpenAlex

Background: Meningococcal serogroup B (MenB) strains are highly diverse. Breadth of immune response for the MenB vaccine, 4CMenB, administered at 0-2, 0-6, or 0-2-6 months, was demonstrated by endogenous complement-human serum bactericidal antibody (enc-hSBA) assay against an epidemiologically relevant panel of 110 MenB strains. Methods: In a phase 3 trial, 3651 healthy 10- to 25-year-old participants were randomized 5:5:9:1 to receive 4CMenB (0-6 schedule), 4CMenB (0-2-6 schedule), investigational MenABCWY vaccine, or control MenACWY-CRM vaccine. The primary objectives were to evaluate safety and demonstrate breadth of immune response by enc-hSBA assay against the MenB strain panel using test-based (percentage of samples without bactericidal activity against strains after 4CMenB vs control vaccination) and responder-based (percentage of participants whose postvaccination sera kill ≥70% strains) approaches. Success was demonstrated with 2-sided 97.5% confidence interval (CI) lower limit >65%. Immunogenicity was assessed by traditional hSBA assay against four indicator strains. Results: Breadth of immune response (test-based) was 78.7% (97.5% CI, 77.2-80.1), 81.8% (80.4-83.1), 83.2% (81.9-84.4) for the 0-2, 0-6, and 0-2-6 schedules, respectively, and (responder-based) 84.8% (81.8-87.5), 89.8% (87.2-92.0), and 93.4% (91.2-95.2), respectively. No clinically relevant differences in immunogenicity were observed across schedules. 4CMenB was well tolerated. Conclusions: The 2-dose (0-2, 0-6) 4CMenB schedules met predefined criteria for success for both breadth of immune response endpoints against a diverse MenB strain panel, had comparable immunogenicity, and safety in line with the established 4CMenB safety profile. The 3-dose schedule provided no additional immunological benefit, supporting use of the 4CMenB 0-2 schedule.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.125
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.001
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.011
GPT teacher head0.283
Teacher spread0.273 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations7
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueOpen Forum Infectious DiseasesSame topicBacterial Infections and VaccinesFrench-language works237,207